secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001104659-25-078135
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Q2 net loss $5.8M; cash runway extended to H1 2027; two directors resign
-----------------------------------------------------------------------------

- Cash, equivalents and marketable securities $39.6M as of Jun 30, expected to fund ops into first half of 2027.
- Net loss $5.8M ($0.13 per share) vs $9.4M ($0.22) in Q2 2024; revenue $0.1M from Finacea royalty.
- Directors Christine Borowski and Anthony Bruno resigned effective Aug 11 and 13, 2025; no dispute with company.
- Repibresib Phase 2b vitiligo trial missed primary endpoint; company seeking partner for program.
- FDA lifted clinical hold on VYN202 Phase 1b for female subjects; partial hold remains for males pending new toxicology study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465925078135/0001104659-25-078135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465925078135/tm2523400d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-078135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer